Immunocore Holdings IMCR
NASDAQ IMCR
$36.13 -1.44 (-3.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2026)

Immunocore Holdings (IMCR) posted Non-Current Assets of $68.3 million for Q1 2026, up 9.96% sequentially from $62.1 million in Q4 2025, and down 13.98% YoY from $79.4 million in Q1 2025.

Analysis

Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2026) Analysis & Trends

Immunocore Holdings has reported Non-Current Assets for 8 years, with the latest figure at $68.3 million in Q1 2026.

  • Quarterly Non-Current Assets fell 13.98% year-over-year to $68.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.4 million (up 5.07% YoY) and the FY2025 annual result came in at $62.1 million, up 11.09% from the prior year.
  • Non-Current Assets advanced to $68.3 million in Q1 2026 per IMCR's latest filing, from $62.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $80.1 million in Q2 2025 and troughed at $48.5 million in Q3 2022.
  • A 5-year average of $65.4 million and a median of $66.5 million in 2024 frame the typical range for Non-Current Assets.
  • The sharpest annual moves came in 2025 and 2026: Non-Current Assets grew 20.42% in 2025, then retreated 13.98% in 2026.
  • Over 5 years, Non-Current Assets stood at $51.2 million in 2022, then increased by 8.24% to $55.4 million in 2023, then climbed by 0.9% to $55.9 million in 2024, then gained by 11.09% to $62.1 million in 2025, then gained by 9.96% to $68.3 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $68.3 million, $62.1 million, and $79.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 Immunocore Holdings 1.85 Bn 965.54 Mn 114.84 Mn 68.38 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 68.38 Mn
Mar 31, 2026 68.29 Mn
Dec 31, 2025 62.10 Mn
Sep 30, 2025 79.65 Mn
Jun 30, 2025 80.09 Mn
Mar 31, 2025 79.38 Mn
Dec 31, 2024 55.90 Mn
Sep 30, 2024 78.73 Mn
Jun 30, 2024 66.51 Mn
Mar 31, 2024 67.95 Mn
Dec 31, 2023 55.40 Mn
Jun 30, 2023 56.69 Mn
Dec 31, 2022 51.18 Mn
Sep 30, 2022 48.50 Mn
Dec 31, 2021 52.64 Mn
Dec 31, 2020 58.45 Mn
Dec 31, 2019 78.90 Mn